MMB-CHMICA, also known as AMB-CHMICA, is a synthetic cannabinoid and designer drug. In the year 2018, it held the distinction of being the sixth most frequently encountered synthetic cannabinoid in substances confiscated by the Drug Enforcement Administration.
|CompTox Dashboard (EPA)||DTXSID301009991|
|Chemical and physical data|
|Molar mass||370.493 g·mol−1|
1. What is MMB-CHMICA (AMB-CHMICA)?
MMB-CHMICA, also known as AMB-CHMICA, is a synthetic cannabinoid and designer drug. It belongs to the class of compounds designed to mimic the effects of natural cannabinoids found in cannabis.
2. How did MMB-CHMICA gain prominence?
In 2018, MMB-CHMICA was recognized as the sixth most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration (DEA) in the United States.
3. What are synthetic cannabinoids?
Synthetic cannabinoids are man-made substances designed to interact with the same receptors in the brain as natural cannabinoids like THC. They are often sprayed onto plant material and sold as a legal or alternative form of marijuana. However, they can have unpredictable and potentially dangerous effects.
4. Is MMB-CHMICA legal and safe to use?
The legality and safety of MMB-CHMICA vary by region and country. Synthetic cannabinoids, in general, have been associated with adverse health effects, including agitation, hallucinations, and even life-threatening conditions. It is essential to be aware of and adhere to local regulations.
5. Can MMB-CHMICA be used for medical purposes?
MMB-CHMICA is not recognized for medical use. It is primarily considered a research chemical or designer drug. Any potential medical applications still need to be established.
6. What are the potential risks associated with MMB-CHMICA use?
Using synthetic cannabinoids like MMB-CHMICA can pose various risks, including physical and mental health hazards, unknown long-term effects, and potential legal consequences. Users should exercise caution.
7. Where can I find more information about MMB-CHMICA?
To obtain a deeper understanding of MMB-CHMICA, consider referring to scientific literature, research studies, and relevant authorities. Staying informed about the latest developments and legal status is crucial for those interested or concerned about this substance.
- In January 2019, Göl E and Çok I conducted a significant assessment of new psychoactive substances in Turkey. Their study focused on narcotics cases evaluated by the Council of Forensic Medicine between 2016 and 2017 in Ankara, Turkey. The findings were documented in “Forensic Science International,” Volume 294, spanning pages 113–123. To explore further details, you can refer to doi:10.1016/j.forsciint.2018.11.003. The PMID for this publication is 30502695, and it is available on S2CID 56176934.
- Mardal M, Dalsgaard PW, Qi B, Mollerup CB, Annaert P, and Linnet K delved into the metabolism of synthetic cannabinoids AMB-CHMICA and 5C-AKB48 in a study conducted in April 2018. Their research involved the analysis of pooled human hepatocytes and rat hepatocytes using UHPLC-(IMS)-HR-MSE. This study was published in the “Journal of Chromatography B,” specifically in Volume 1083, spanning pages 189–197. For more information, you can refer to doi:10.1016/j.jchromb.2018.03.016, and the PMID for this publication is 29549742.
- In October 2022, Wagmann L, Stiller RG, Fischmann S, Westphal F, and Meyer MR delved deeper into the toxicokinetics of synthetic cannabinoids. Their research explored the in vitro contribution of human carboxylesterases. This study was documented in “Archives of Toxicology,” Volume 96, Issue 10, spanning pages 2755–2766. To gain further insights, refer to doi:10.1007/s00204-022-03332-z. This publication can also be found on PMC (PubMed Central) with the identifier PMC 9352624, and the PMID is 35788413.
- The “Emerging Threat Report: Annual 2018” (PDF) was published by the Special Testing and Research Laboratory of the Drug Enforcement Administration. This report provides insights into emerging threats in the field of drug enforcement and testing.